Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab/tuvonralimab + Surgery in Relapsed Ovarian Cancer
NCT06602063Phase 2Not yet recruiting
- Sponsor
- Shanghai Gynecologic Oncology Group
- Start
- Jul 2025
- Primary completion
- Jun 2030
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of iparomlimab + tuvonralimab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (3 arms), sponsored by Shanghai Gynecologic Oncology Group. Primary endpoints: Progression-free survival up to 3 years and 3-years Overall Survival Rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT06602063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06602063.